Targeting activated mineralocorticoid receptor: Occam's razor revisited

Kidney International
|September 1, 2012
PubMed

Insights

Mineralocorticoid receptor (MR) activation, linked to inflammation and fibrosis, can be triggered by aldosterone or endogenous glucocorticoids. Reactive oxygen species may enhance glucocorticoid-induced MR activation, even without aldosterone.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pathology

Background:

  • Mineralocorticoid receptors (MRs) are traditionally linked to electrolyte transport.
  • Emerging evidence shows MR activation contributes to tissue inflammation and fibrosis.
  • Aldosterone is a primary MR activator, but endogenous glucocorticoids can also activate MR under specific conditions.

Purpose of the Study:

  • To elucidate the mechanisms of MR activation beyond aldosterone.
  • To investigate the role of endogenous glucocorticoids in MR activation.
  • To explore factors influencing glucocorticoid-induced MR activation.

Main Methods:

  • Review of existing literature on MR signaling pathways.
  • Analysis of studies investigating glucocorticoid interactions with MR.
  • Examination of the role of 11β-hydroxysteroid dehydrogenase and reactive oxygen species in MR regulation.

Main Results:

  • Endogenous glucocorticoids (cortisol, corticosterone) can activate MR.
  • Tissue-specific enzymes like 11β-hydroxysteroid dehydrogenase typically limit glucocorticoid-induced MR activation.
  • Reactive oxygen species can promote glucocorticoid-induced MR activation, independent of aldosterone.

Conclusions:

  • MR activation has broader implications than electrolyte balance, including inflammatory and fibrotic processes.
  • Glucocorticoid-induced MR activation is a significant pathway, modulated by local enzymatic activity and oxidative stress.
  • Understanding these pathways is crucial for developing targeted therapies for MR-related diseases.

Related Concept Videos

Spare Receptors01:30

Spare Receptors

Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...